Heptanoyl-coenzyme A (heptanoyl-CoA) is a derivative of CoA that contains the medium-chain fatty acid heptanoic acid .[1] It inhibits butyryl-CoA:acetate-CoA transferase isolated from the gut bacteria P. elsdenii when used at a concentration of 200 µM. Heptanoyl-CoA levels are increased in primary fibroblasts derived from patients with medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in the presence of heptanoic acid, indicating heptanoyl-CoA formation by short-chain acyl-transferases.[2] It blocks decreases in infarct volume and improvements in motor function induced by the isoquinoline alkaloid berberine in a mouse model of ischemic stroke induced by middle cerebral artery occlusion (MCAO) when administered at a dose of 0.4 mg/kg per day.[3]
References:
[1].Schulman, M., and Valentino, D.Kinetics and catalytic properties of coenzyme A transferase from Peptostreptococcus elsdeniiJ. Bacteriol.128(1)372-378(1976).
[2].Karunanidhi, A., Basu, S., Zhao, X.-J., et al.Heptanoic and medium branched-chain fatty acids as anaplerotic treatment for medium chain acyl-CoA dehydrogenase deficiencyMol. Genet. Metab.140(3)107689(2023).
[3].Duan, H., Hu, J., Deng, Y., et al.Berberine mediates the production of butyrate to ameliorate cerebral ischemia via the gut microbiota in miceNutrients16(1)9(2023).